Program moderator Bruce Feinberg, DO, explains that new drugs for the treatment of cancer hold promise in terms of efficacy; however, these medications come at a high financial cost for patients and payers.
Although the initial drug in a new class of medications is associated with a high price when first released, the price tends to come down substantially when a second drug in the same class is introduced, comments Scott Gottlieb, MD. As an example, he highlights how Sovaldi, a drug for the treatment of hepatitis C, was launched at a high price, and how the price of Sovaldi decreased after the introduction of Harvoni. Dr Gottlieb explains that competition resulting from the entry of additional products that ultimately treat the same underlying disease can affect drug pricing.
Current policies do not often allow second- and third-in-class drugs to enter the market as efficiently as first-in-class drugs, remarks Dr Gottlieb. He notes that the regulatory process for first-in-class drugs is much different from the regulatory process for subsequent drugs. Policy changes that allow subsequent drugs a more favorable entry path could help address concerns regarding drug pricing, suggests Dr Gottlieb.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD
May 2nd 2024Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.
Read More